OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023 07:30 ET
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
June 22, 2023 07:30 ET
|
OpGen, Inc.
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30 instruments optimized for series production and clinical...
OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference
June 20, 2023 07:30 ET
|
OpGen, Inc.
‘Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens’ presented on June 17th, 2023Presentation focused on primary study...
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero...
OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., May 08, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter...
OpGen Announces Closing of $3.5 Million Public Offering
May 04, 2023 16:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Pricing of $3.5 Million Public Offering
May 01, 2023 21:00 ET
|
OpGen, Inc.
ROCKVILLE, Md., May 01, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
April 26, 2023 16:30 ET
|
OpGen, Inc.
Triggers milestone payment of approximately $0.3 million ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company...
OpGen Enters Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
April 18, 2023 16:30 ET
|
OpGen, Inc.
Fisher Healthcare, a part of Thermo Fisher Scientific, will become the non-exclusive national laboratory distribution partner alongside OpGen, Inc.’s direct sales in the U.S. for the Unyvero A50...
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
April 18, 2023 07:30 ET
|
OpGen, Inc.
Based on large multi-center study with over 1,800 patient samplesPrimary endpoint for Unyvero UTI for urinary tract infection was successfully met and shows overall weighted average sensitivity of...